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doi:10.1016/j.ijid.2004.02.007Objective: To determine the peak time of outbreak of Crimean-Congo haemorrhagic
fever (CCHF) and to highlight the disease-specific areas in the Balochistan province of
Pakistan.
Design: A hospital-based case-series study.
Place and Duration: A five-year study was conducted by the Department of Pathology
in collaboration with the Department of Medicine, Sandeman Provincial Teaching
Hospital, Quetta, Balochistan, Pakistan, from 1 March 1997 to 28 February 2002.
Patients and methods: A total of 135 cases were included in the study based on a high
index of suspicion of CCHF. The mean age was 33.5  18.7 years. Two sets of blood
samples were drawn on admission; one set was sent for urgent routine investigations
while the other was sent to CDC, Atlanta, USA, for confirmation.
Results: The study showed that CCHF was more common between March and May and
again, between August and October, depicting a bi-annual surge. Out of 135 suspected
cases, 83 (61.4%) were confirmed to have CCHF and were given platelet concentrate
and ribavirin. It was observed that CCHF was more common in specific areas of the
province.
Conclusions: It is essential to raise the level of knowledge regarding CCHF, especially
in disease-specific areas, focussing on the peak outbreak periods.
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rights reserved.ress: 18 Dads Wood Apartments, Harlow, Essex CM20 1JG, UK.
tmail.com (A.S. Sheikh).
l Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
38 A.S. Sheikh et al.Introduction
Crimean-Congo haemorrhagic fever (CCHF) is a viral
haemorrhagic fever of the Nairovirus group. CCHF
occurs sporadically in regions of Africa, Asia and
Eastern Europe1 with case fatality rates ranging
from 13—90%.2—4 It was recognized in Pakistan in
1976, when a laparotomy was performed on a
patient with abdominal pain, haematemesis and
melaena.5 Eleven secondary cases in hospital staff
resulted in three deaths, including a surgeon
and an operating theatre attendant.5 Since then
similar nosocomial outbreaks have been reported
in 1979 in Dubai (five secondary infections,
two deaths),6 in 1979 in Iraq (two secondary
infections, two deaths),7 in 1984 in South Africa
(eight secondary infections, two deaths)8 and in
1994, again, in Pakistan (three secondary infec-
tions).9 During 2001, cases or outbreaks have been
reported in Kosovo, Albania, Iran, Pakistan and
South Africa.9
Humans who become infected with CCHF acquire
the virus from direct contact with blood or other
infected tissues from infected persons or livestock
or they may become infected from a tickbite.9,10
The majority of cases have occurred in those
involved with the livestock industry, such as agri-
cultural workers, slaughterhouse workers and veter-
inarians.9,11 The virus enters the blood and involves
most of the organs including the liver, lungs and
lymphoid tissue.12 In severe cases, hepatorenal and
pulmonary failure, accompanied by impaired coa-
gulation leading to haemorrhage, are characteris-
tic.13
The risk of person-to-person transmission is high-
est during the later stages of illness; CCHF infection
has not been reported in persons whose contact with
an infected patient occurred only during the incu-
bation period i.e. before the patient became feb-
rile.14,15
General supportive therapy is the mainstay of
patient management in CCHF; maintenance of ade-
quate blood volume and blood component replace-
ment is required.11 The antiviral drug ribavirin has
been used in treatment of established CCHF infec-
tion.16
There have been many outbreaks of CCHF in the
Balochistan province of Pakistan resulting in the loss
of many lives.1,5 This study was conducted in order
to determine the peak time of outbreak of the
disease, with a focus on the specific areas in which
the disease is highly concentrated. It also concen-
trates on the common clinical manifestations of the
disease, so as to lessen the chances of misdiagnosis
in future.Patients and methods
This case-series study was conducted by the Depart-
ment of Pathology in collaboration with the Depart-
ment of Medicine, Sandeman Provincial Teaching
Hospital, Quetta, which is the largest hospital and
the only tertiary-care referral facility in the pro-
vince of Balochistan. The study period extended
over five years between 1 March 1997 to 28 February
2002. The mean age of the patients was 33.5  18.7
years. The major criteria for admission were a short
history of high grade fever (<two weeks) associated
with bleeding from more than one site e.g. haema-
temesis, haematuria, melaena, epistaxis, etc. and a
serial reduction in platelet count. The study
included a total of 135 cases who presented to
the Medical Emergency Department, of whom there
were 87 (64%) males and 48 (36%) females.
All 135 cases who fulfilled the major criteria for
admission were provisionally diagnosed with CCHF.
All patients were carefully examined under strict
precautionary and isolatory conditions, according to
the recommended standard protocol. A 24-hour
referral laboratory was affiliated with the Depart-
ment of Medicine to provide all the required inves-
tigations. All the patients were initially kept in the
isolation unit of the hospital and were transferred
out if the diagnosis of CCHF proved negative.
On admission, two sets of blood samples were
drawn under precautionary measures and sent to
the laboratory; one set for immediate testing for
complete blood count (CBC), platelet count, pro-
thrombin time (PT), and activated partial thrombo-
plastin time (APTT) and the other preserved for
future testing, for example of liver function,
according to the advice of the medical expert.
The laboratory staff were also warned of precau-
tionary steps. The specimens were processed
according to the transport protocol laid down by
CDC, Atlanta, USA for specimens of infectious dis-
eases. The samples were transported to the Public
Health Division of the National Institute of Health
(NIH), Islamabad, Pakistan, which is a one-hour
flight from the study region. On the same day, a
parcel of samples was transported to CDC, Atlanta,
USA by air. The CDC laboratory at Atlanta reported
on the samples and results were conveyed via fax/e-
mail, both to NIH Islamabad and to the hospital in
Quetta. The time span from collection of specimens
to reporting test results in this study took less than
96 hours.
All the attendants and close contacts of the
patients were kept under observation. Complete
blood count, coagulation profile and hepatic profile
were taken serially every third day. Five healthcare
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Table 3 Frequency of haemorrhagic signs and symp-
toms in patients with CCHF.
Symptoms No. of patients (%)
Epistaxis 67 (80.7%)
Haematemesis 49 (59.0%)workers, including a staff nurse, two washermen
and two sweepers were exposed to the secretions of
the infected patients. They were treated prophy-
lactically according to the standard recommended
protocol.Melaena 42 (50.6%)




Out of 135 cases who were admitted with a high
index of suspicion of CCHF, 83 (61.5%) cases were
confirmed as having CCHF on the basis of viral
detection in the blood by CDC, Atlanta, USA. Nine
(10.8%) cases were positive for CCHF by PCR, 22
(26.5%) showed positivity of IgM against CCHF while
52 (62.6%) showed positivity of IgM as well as IgG
against CCHF, detected by ELISA. The mean time
between the first clinical manifestation and hospi-
talization was 3.82  0.64 days.
The final diagnoses of the 135 patients entered
into the study are shown in Table 1. The common
clinical presentations of the 83 confirmed cases of
CCHF are shown in Table 2. Fever and haemorrhage
were the most common presentations with a fre-
quency of 100%. Among haemorrhagic signs and




Crimean-Congo haemorrhagic fever 83 (61.5%)
Idiopathic thrombocytopaenic purpura 10 (7.4%)
Aplastic anaemia 22 (16.3%)
Acute lymphoblastic leukaemia 11 (8.1%)
Acute myeloblastic leukaemia 9 (6.7%)
n = 135.
Table 2 Common clinical presentations of patients
with CCHF.










Sore throat 19 (22.9%)
Cough 22 (26.5%)
Malaise 65 (78.3%)
n = 83.haematemesis, melaena, gum bleeding, petechiae
and haematuria were less commonly seen, as shown
in Table 3. The laboratory investigations of patients
with CCHF are shown in Table 4.
All 135 patients meeting the case definition cri-
teria of CCHF were treated according to the WHO
protocol for CCHF treatment. The treatment was
continued in 83 (61.5%) patients who were con-
firmed retrospectively as having CCHF by CDC,
Atlanta, USA, and discontinued in the rest of the
patients. The recommended protocol is intravenous
ribavirin, which was not available, so oral ribavirin
was given in a 2 g loading dose, followed by 4 g in
four divided doses for 4 days and then 2 g in four
divided doses for six days. The mean time from the
first clinical manifestation to the administration of
ribavirin was 6.20  0.76 days. In addition, platelet
concentrate was given to all the cases. Symptomatic
treatment, such as paracetamol, was given for pyr-
exia. The patients were kept in strict isolation for
15—21 days. The clinical and laboratory responses to
treatment were gradual. The mean time from
patients starting ribavirin to the patients becoming
afebrile was 2.30  0.69 days. The platelet counts
recovered 10—14 days after the onset of illness in
the survivors. The patients tolerated ribavirin well,
with no significant side effects apart from mild
anaemia (Hb: 9—11 g/dl) and thrombocytosis
(platelet count up to 560  109/L) after completing
the ten-day course. Unfortunately, eight (9.6%)
out of 83 cases of CCHF died, including a staff
nurse who had a needlestick injury while handling
blood of a patient, two washermen and two
sweepers who were exposed to the secretions of
patients with CCHF, although they had been given
the recommended post-exposure prophylaxis. The
secretion that the workers were exposed to most
frequently was blood, followed by vomitus, sweat,
saliva, urine, stool in descending order. Severe
bleeding, acute respiratory distress syndrome
(ARDS) and disseminated intravascular coagulation
(DIC) were the significant causes of death in these
eight patients.
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Table 4 Laboratory investigations of patients with CCHF.
Laboratory test No. of patients (%) Values mean  S.D. Normal range
Haemoglobin (g/dL) 83 (100%) 8.7  1.5 M: 14—18/F: 12—16
Total leukocyte count (109/L) 68 (81.9%) 3.3  1.1 4—11
Platelet count (109/L) 83 (100%) 27.1  15.6 150—450
APTT (sec) 65 (78.3%) 117.4  22.4 24—31
Prothrombin time (sec) 71 (85.5%) 13.1  2.0 12—16
AST (U/L) 57 (68.7%) 409.1  152.4 15—42
ALT (U/L) 42 (50.6%) 46.2  18.0 5—35
Total bilirubin (mg/dL) 27 (32.5%) 3.1  1.2 0.2—1.2
n = 83; APTT: Activated partial thromboplastin time; AST: Aspartate aminotransferase; ALT: Alanine transaminase.This five-year study shows that CCHF occurs at a
specific time of the year. Most of the cases of CCHF
were seen during the months of March to May and
then again in August to October, i.e. there is a bi-
annual surge of the disease. Very few cases were
seen during the rest of the year, as shown in Figure 1.
This bi-annual surge of the disease may be related to
the seasonal weather changes in this part of the
world or it may be related to the lifestyle patterns of
the people living here.
It was also noticed that the distribution of
CCHF was more common in specific districts of
Balochistan covering a 400 km belt. The biggest
percentage of cases were from Harnai and there
were a decreasing number of cases seen in other
areas including Quetta, Loralai, Barkhan, Kohlu,
Zhob, Musa Khel, Mekhtar and Mastung, as shown
in Figure 2.
The distribution of the cases by occupation
showed that slaughter-house workers were the
most frequently represented, with 46% of cases,
while shepherds (21%), gypsies (campers) (11%),
farmers (8%), healthcare workers (6%), military per-
sonnel (5%) and milkmen (3%) showed a lesser fre-
quency.Figure 1 Month-wise serial distributDiscussion
This study shows that there is a bi-annual surge of
the disease. Awareness of this disease pattern is
important from the point of view of outbreaks in this
part of the world as it enables health authorities to
target their limited resources for preventative mea-
sures during these months. Furthermore, it has been
shown that the disease is more prevalent in specific
areas of Balochistan and among specific occupa-
tions. Health policy makers can therefore concen-
trate on these areas to educate the people by
increasing awareness of the common signs and
symptoms of the disease thereby preventing further
loss of life.
Healthcare workers are at risk of acquiring infec-
tion from needlestick injuries during surgical pro-
cedures and while managing patients with CCHF.9
Healthcare workers who have had contact with
tissue or blood from patients with suspected or
confirmed CCHF should be followed-up with daily
temperature and symptommonitoring for at least 14
days after the putative exposure.9
The clinical course in the patients was consistent
with published reports of CCHF.5—8,16—18 Thoughion of CCHF patients 1997—2002.
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Figure 2 Area-wise distribution of CCHF patients. QTA:
Quetta; LOR: Loralai; HAR: Harnai; MAS: Mastung; BAR:
Barkhan; KOH: Kohlu; MEKH: Mekhtar; MUSA: Musa Khel;
ZHOB: Zhob; KIN: Kingri.rarely diagnosed, CCHF is known and feared in
Pakistan among medical staff.5 Patients should be
managed conservatively, with supportive care giving
particular attention to haematological and fluid
imbalances.19 Simple barrier nursing procedures
are protective and should be immediately and rig-
orously applied.20
The antiviral drug ribavirin has been used in the
treatment of established CCHF infection with appar-
ent benefit.9,21 Both oral and intravenous formula-
tions seem to be effective.9 Oral ribavirin has been
used for post-exposure prophylaxis for CCHF infec-
tion but its efficacy has not been formally assessed.
The choice of oral treatment was dictated by avail-
ability and it was fortunate that all the patients in
this study were able to tolerate the drug by mouth.
Ribavirin is well absorbed from the gastrointestinal
tract22 and most patients would be expected to
attain levels in the blood comparable with in-vitro
sensitivity of CCHF to ribavirin.23
The clinical and laboratory responses to treat-
ment with ribavirin were rapid. The platelet counts
recovered 8—10 days after the onset of illness, (48 h
after starting ribavirin), in patients who survived.
Illness-to-infection ratios in secondary infections
have always been high, and mortality is 15—100%
in severe disease.3—5,17,18 The data in this study
suggest ribavirin may have had a beneficial effect
on outcome in the patients.
CCHF is a rarely diagnosed disease, but it occurs
in remote rural communities over a vast geographic
range.4,17,24 A placebo-controlled trial is unlikely
ever to be carried out and would probably be inap-
propriate. The following ribavirin treatment regi-
men could be used in endemic and remote areas:
intravenous or oral regimens to deliver a 2 g loading
dose, then 4 g/day in four divided doses, six hourly
for four days, dropping to 2 g/day for six days (totaltreatment time ten days). Such a dose can be
tolerated for a short period, in line with experience
gained during the treatment of Lassa fever in
West Africa,21 and should achieve virucidal serum
levels.23
Oral treatment provides simplicity, cheapness
and safety in areas where medical facilities may
be limited and the misuse of needles may endanger
staff or other patients. Systematic measurements to
monitor drug efficacy should be collected, including
clinical observations and outcome, temperature,
white cell and platelet counts, and liver enzymes.
Results could be reported to a central body such as
the World Health Organization (WHO) and compared
with published retrospective data on untreated
patients. The WHO or other central body could
prepare instructions for diagnosis, data collection,
safety, and arrange for treatment to be distributed
to endemic areas. In this way, there is some prospect
of gathering data to support recommendations for
the treatment of this life-threatening infection.Acknowledgements
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